The current research was carried to estimate and validate the formulation of a Docosahexaenoic acid ophthalmic emulsion, intended for ocular medication delivery. Certain ophthalmic diseases such as dry eye syndrome which leads to ophthalmic inflammation is affecting ocular health very drastically so in search of effective cure docosahexaenoic acid microemulsion has withstood all the analysis. Many times, when formulation is taken as capsules, less of the medication reaches the area of the eye that is inflamed; therefore, a higher dose is needed, yet the inflammation remains dangerous. Because of this, DHA can be produced as eye drops for direct ocular administration. Taking a source of docosahexaenoic acid, thin layer chromatography was used to identify the isolated chemical by comparing it to standard DHA. The separated chemicals were subjected to additional examination using gas chromatography. The emulsion had a white color, 0.4 micrometer is the particle size, with viscosity of 30.41 cp, and was steady at a temperature range of 25 - 40 ºC. The created emulsion was also shown to have the same physical characteristics. The produced micro emulsions were assessed for zeta potential, pH, viscosity, and drug content. The optimized micro emulsion formulation had the highest in-vitro drug penetration (85%), a pH - 7.1 and a viscosity of 30.4 cp. Overall the novel DHA containing microemulsion shows promising effects on eye health.